Genprex, Inc. Files 8-K with Corporate Updates
Ticker: GNPX · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1595248
Sentiment: neutral
Topics: corporate-filing, 8-K
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K on Sept 4th detailing corporate info. Nothing major, just housekeeping.
AI Summary
Genprex, Inc. filed an 8-K on September 4, 2024, reporting other events and financial statements. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 3300 Bee Cave Road, #650-227, Austin, TX 78746. The company's telephone number is (512) 537-7997.
Why It Matters
This filing provides essential corporate information and updates for Genprex, Inc., which is crucial for investors and stakeholders to understand the company's structure and operational details.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any new material risks or significant financial events.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- September 4, 2024 (date) — Date of report
- 3300 Bee Cave Road, #650-227, Austin, TX 78746 (address) — Principal executive offices
- Delaware (jurisdiction) — State of incorporation
- (512) 537-7997 (phone_number) — Registrant's telephone number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 4, 2024.
In which state was Genprex, Inc. incorporated?
Genprex, Inc. was incorporated in Delaware.
What is the principal executive office address for Genprex, Inc.?
The principal executive office address is 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the telephone number for Genprex, Inc.?
The telephone number for Genprex, Inc. is (512) 537-7997.
What is the SIC code for Genprex, Inc.?
The Standard Industrial Classification (SIC) code for Genprex, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,155 words · 5 min read · ~4 pages · Grade level 16.8 · Accepted 2024-09-04 09:30:39
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20240703_8k.htm (8-K) — 32KB
- 0001437749-24-028339.txt ( ) — 163KB
- gnpx-20240904.xsd (EX-101.SCH) — 3KB
- gnpx-20240904_def.xml (EX-101.DEF) — 11KB
- gnpx-20240904_lab.xml (EX-101.LAB) — 15KB
- gnpx-20240904_pre.xml (EX-101.PRE) — 11KB
- gnpx20240703_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 4, 2024, Genprex, Inc. ("Genprex" or the "Company") issued a press release announcing the Company's intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D). The spin-out, if completed as presently contemplated, would result in NewCo focusing on developing GPX-002, while Genprex would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates Genprex's strong ongoing commitment to the Company's streamlined, focused strategies and ongoing research and development prioritization initiative. The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024, subject to adequate financing, the satisfaction of customary conditions and final approval from the Genprex management and Board of Directors. The Company's goal for separating the diabetes clinical development program from its oncology program follows closely behind Genprex's recent announcement to re-focus its oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa Gene Therapy. As previously announced, the Company continues to evaluate ways to optimize its clinical and research programs and operational strategies. Additionally, the Company is considering various strategic alternatives and opportunities to enhance stockholder value. Cautionary Language Concerning Forward-Looking Statements
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: September 4, 2024 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)